← Back to patent-cliff list
AZD9550
Tier C — Watch / tradeAZD9550
AstraZeneca
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GLP1R, GCGR
Indications (approved)：Overweight, Obesity, Hepatic function decline, Non-alcoholic steatohepatitis
Regional status
US
Phase II
2025-02-18
EU
Phase II
2023-09-29
China
Phase II
2025-05-20
Japan
Phase II
2023-09-29
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of AZD9550?
Approved indications include: Overweight, Obesity, Hepatic function decline, Non-alcoholic steatohepatitis.
When does the AZD9550 patent expire?
No public expiry year is available for AZD9550 yet; this page updates once verified.
How do I get a quote for AZD9550 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02